Recursion Pharmaceuticals (RXRX) Stock Sinks As Market Gains: What You Should Know

Company Performance - Recursion Pharmaceuticals (RXRX) closed at $3.42, reflecting an -8.06% change from the previous day, underperforming the S&P 500 which gained 0.69% [1] - Prior to the latest trading session, RXRX shares had decreased by 25%, lagging behind the Medical sector's gain of 0.77% and the S&P 500's loss of 1% [1] Upcoming Financial Results - Recursion Pharmaceuticals is set to announce its earnings on February 25, 2026, with an expected EPS of -$0.28, indicating a 47.17% growth compared to the same quarter last year [2] - Revenue is projected to be $25.5 million, representing a significant 460.44% increase compared to the year-ago quarter [2] Full-Year Estimates - The Zacks Consensus Estimates for RXRX indicate expected earnings of -$1.59 per share and revenue of $64.62 million, reflecting year-over-year changes of +5.92% and +9.83%, respectively [3] - Recent modifications to analyst estimates for Recursion Pharmaceuticals suggest positive near-term business trends, with positive revisions seen as a favorable sign for the business outlook [3] Zacks Rank and Industry Performance - Recursion Pharmaceuticals currently holds a Zacks Rank of 2 (Buy), with the Zacks Consensus EPS estimate remaining unchanged over the past month [5] - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 87, placing it in the top 36% of over 250 industries, indicating strong performance potential [6]